Telix Pharmaceuticals (TLX) Share Forecast & Price Target

Compare

316 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TLX Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Telix

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TLX Stock 12 Month Forecast

Average Price Target

AU$34.88

▲(33.63%Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Telix Pharmaceuticals in the last 3 months. The average price target is AU$34.88 with a high forecast of AU$35.98 and a low forecast of AU$33.98. The average price target represents a 33.63% change from the last price of AU$26.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"AU$13","36":"AU$36","18.75":"AU$18.75","24.5":"AU$24.5","30.25":"AU$30.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35.98259050392048,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$35.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.8779349316,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$34.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.98355769814712,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$33.98</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,18.75,24.5,30.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.99,28.604814654147727,29.219629308295456,29.834443962443185,30.449258616590914,31.064073270738643,31.67888792488637,32.293702579034104,32.90851723318183,33.52333188732956,34.13814654147729,34.75296119562502,35.36777584977275,{"y":35.98259050392048,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.99,28.519841148584614,29.04968229716923,29.579523445753846,30.109364594338462,30.639205742923078,31.169046891507694,31.698888040092307,32.22872918867692,32.75857033726154,33.288411485846154,33.81825263443077,34.348093783015386,{"y":34.8779349316,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.99,28.45104289985747,28.91208579971494,29.373128699572412,29.834171599429883,30.295214499287354,30.756257399144825,31.217300299002297,31.678343198859768,32.13938609871724,32.60042899857471,33.06147189843218,33.52251479828965,{"y":33.98355769814712,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.67,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.15,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.09,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.97,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetAU$35.98

Average Price TargetAU$34.88

Lowest Price TargetAU$33.98

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

AU$28

Buy

7.28%

Upside

Upgraded

05/30/25

Telix Pharmaceuticals Ltd. shows strong financial performance driven by excellent revenue growth and strategic initiatives outlined in its earnings call. However, the high P/E ratio suggests potential overvaluation, and technical indicators reveal bearish momentum. Cash flow management remains a concern. Despite potential regulatory and market risks, the company's growth prospects and innovative product pipeline support a favorable outlook.

Shane StoreyWilsons

Wilsons

AU$35

Buy

34.10%

Upside

Reiterated

05/08/25

Wilsons Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

John HesterBell Potter

Bell Potter

AU$36→AU$34

Buy

30.27%

Upside

Reiterated

04/29/25

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Alnylam Pharma (NASDAQ: ALNY)

David DaiUBS

UBS

AU$36

Buy

37.93%

Upside

Reiterated

04/29/25

UBS Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Matthew TaylorJefferies

Jefferies

AU$33.7→AU$34.5

Buy

32.18%

Upside

Reiterated

04/28/25

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals Ltd. (Other OTC: TLPPF), Encompass Health (NYSE: EHC) and Revolution Medicines (NASDAQ: RVMD)

Tara BancroftTD Cowen

TD Cowen

AU$35

Buy

34.10%

Upside

Reiterated

04/22/25

Telix Pharmaceuticals: Strong Financial Performance and Promising Growth Prospects Lead to Buy Rating

Steven WheenJarden

Jarden

AU$29.14

Buy

11.65%

Upside

Reiterated

02/23/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Dennis HulmeTaylor Collison

Taylor Collison

AU$19.61

Buy

-24.87%

Downside

Reiterated

08/26/24

Taylor Collison Remains a Buy on Telix Pharmaceuticals Ltd. (TLPPF)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

AU$28

Buy

7.28%

Upside

Upgraded

05/30/25

Shane StoreyWilsons

Wilsons

AU$35

Buy

34.10%

Upside

Reiterated

05/08/25

Wilsons Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

John HesterBell Potter

Bell Potter

AU$36→AU$34

Buy

30.27%

Upside

Reiterated

04/29/25

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Alnylam Pharma (NASDAQ: ALNY)

David DaiUBS

UBS

AU$36

Buy

37.93%

Upside

Reiterated

04/29/25

UBS Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Matthew TaylorJefferies

Jefferies

AU$33.7→AU$34.5

Buy

32.18%

Upside

Reiterated

04/28/25

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals Ltd. (Other OTC: TLPPF), Encompass Health (NYSE: EHC) and Revolution Medicines (NASDAQ: RVMD)

Tara BancroftTD Cowen

TD Cowen

AU$35

Buy

34.10%

Upside

Reiterated

04/22/25

Telix Pharmaceuticals: Strong Financial Performance and Promising Growth Prospects Lead to Buy Rating

Steven WheenJarden

Jarden

AU$29.14

Buy

11.65%

Upside

Reiterated

02/23/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Dennis HulmeTaylor Collison

Taylor Collison

AU$19.61

Buy

-24.87%

Downside

Reiterated

08/26/24

Taylor Collison Remains a Buy on Telix Pharmaceuticals Ltd. (TLPPF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Telix Pharmaceuticals

1 Month

xxx

Success Rate

18/29 ratings generated profit

Average Return

+4.17%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.07% of your transactions generating a profit, with an average return of +4.17% per trade.

3 Months

xxx

Success Rate

21/29 ratings generated profit

Average Return

+17.47%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.41% of your transactions generating a profit, with an average return of +17.47% per trade.

1 Year

Steven WheenJarden

Success Rate

17/18 ratings generated profit

Average Return

+72.18%

reiterated a buy rating 3 months ago

Copying Steven Wheen's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +72.18% per trade.

2 Years

xxx

Success Rate

17/18 ratings generated profit

Average Return

+162.93%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 94.44% of your transactions generating a profit, with an average return of +162.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TLX Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TLX has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TLX average Analyst price target in the past 3 months is 34.88.

Each month's total comprises the sum of three months' worth of ratings.

TLX Financial Forecast

TLX Earnings Forecast

Next quarter’s earnings estimate for TLX is AU$0.35 with a range of AU$0.35 to AU$0.35. The previous quarter’s EPS was AU$0.06. TLX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.00% of the time in the same period. In the last calendar year TLX has Preformed in-line its overall industry.

TLX Sales Forecast

Next quarter’s sales forecast for TLX is AU$244.95M with a range of AU$235.50M to AU$254.40M. The previous quarter’s sales results were AU$419.24M. TLX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.40% of the time in the same period. In the last calendar year TLX has Outperformed its overall industry.

TLX Stock Forecast FAQ

What is AU:TLX’s average 12-month price target, according to analysts?

Based on analyst ratings, Telix Pharmaceuticals Ltd.’s 12-month average price target is 34.88.

What is AU:TLX’s upside potential, based on the analysts’ average price target?

Telix Pharmaceuticals Ltd. has 33.63% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Telix Pharmaceuticals Ltd. a Buy, Sell or Hold?

Telix Pharmaceuticals Ltd. has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Telix Pharmaceuticals Ltd.’s share price target?

The average share price target for Telix Pharmaceuticals Ltd. is 34.88. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is AU$35.98 ,and the lowest forecast is AU$33.98. The average share price target represents 33.63% Increase from the current price of AU$26.1.

What do analysts say about Telix Pharmaceuticals Ltd.?

Telix Pharmaceuticals Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Telix Pharmaceuticals Ltd.?

To buy shares of AU:TLX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Telix Pharmaceuticals (TLX) Share Forecast & Price Target

TLX Analyst Ratings

TLX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Telix Pharmaceuticals

TLX Analyst Recommendation Trends

TLX Financial Forecast

TLX Earnings Forecast

TLX Sales Forecast

TLX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts